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Abstract 

Introduction: Multiple reforms in Sweden have appreciably enhanced prescribing efficiency for the PPIs, statins and renin-angiotensin inhibitor drugs. There is the potential to extend this to atypical antipsychotic drugs (AAPs) given their considerable expenditure globally and oral generic risperidone became available in Sweden from January 2009. However schizophrenia and bipolar disease are complex to treat and there is a need to tailor treatments given the considerable inter patient variability in side-effects between AAPs and patient responses to treatment. Objective: Assess changes in risperidone utilisation before and after oral generic risperidone was reimbursed in January 2009 alongside any specific demand-side measures. In addition (a) assess the rate of price reductions for risperidone over time as well as overall expenditure on AAPs; (b) suggest additional measures that could potentially be introduced; and (c) provide guidance to other European countries on the implications of any findings. Method: Principally a retrospective observational study and interrupted time series design. Key findings: No specific measures to encourage the prescribing of risperidone, and no appreciable change in its utilisation, after generics reimbursed. Oral risperidone was 96% generic, and its price 80% below pre-patent loss prices, by August 2011. This limited the increase in AAP expenditure compared with the increase in utilisation after generics. Conclusion: No apparent effectiveness or safety problems with generic risperidone. Authorities cannot rely on a spill over from other disease areas to effect changes in physician prescribing habits. Specific measures are needed to encourage the prescribing of generic AAPs first line where appropriate, exacerbated by the complexity of the disease areas. Likely that their influence will be limited by greater need to tailor treatments compared with acid-related stomach disorders or hypercholesterolemia.   

Introduction

	General

National and regional (county) authorities in Sweden have instigated multiple measures to encourage the prescribing of generics at low prices versus originators and patented products in a class or related class where the products are seen as similar in all or nearly all patients [1-10]. These include the proton pump inhibitors (PPIs), statins and renin-angiotensin inhibitor drugs [1-16]. Initiatives in Sweden include compulsory generic substitution, production of prescribing guidance and formularies such as the ‘Wise List’ in Stockholm County, academic detailing, prescribing indicators linked with financial incentives and reimbursement restrictions [1-14]. These activities mirror the demand-side measures introduced in other European countries including guidelines, academic detailing, benchmarking of physician prescribing habits, quality and efficiency prescribing indicators, financial incentives for physicians, patients and pharmacists as well as prescribing restrictions [3-7,10,14-18].
 
The various reforms and initiatives in Sweden resulted in the following between 2001 and 2007 [3-6]:
	49% reduction in expenditure for the PPIs despite a 53% increase in utilisation
	39% reduction in expenditure for the statins despite a 3.2 fold increase in utilisation
	Stable expenditure on renin-angiotensin inhibitor drugs despite a 92% increase in utilisation

The potential for authorities to encourage the prescribing of low cost generics has been made possible by the required bioequivalence between generics and originators necessary for market authorisation of generics in Europe [3,7,14,19-21]. 

Care has not been compromised in Sweden through these various initiatives. This is demonstrated by a recent ecological study showing similar reductions in lipid levels and blood pressure for patients with hypercholesterolemia or hypertension whether they were prescribed generic simvastatin or generic Angiotensin Converting Enzyme Inhibitors (ACEIs) or non-formulary drugs such as patented atorvastatin or Angiotensin Receptor Blockers (ARBs) respectively [22]. There have also been active switching programmes among European countries and regions, including Sweden, to take advantage of low cost statins and ARBs versus existing patented products in these two classes [10,14,16,17,23,24]. This again without appearing to compromising care [16,17,23,24].

	Atypical antipsychotic drugs

There has been growing interest among authorities regarding the prescribing of atypical antipsychotic drugs in view of their budget impact, with worldwide sales at over $US5bn per year in the early 2000s and reaching $14.6bn in the US in 2009 [25-27]. In addition, medication costs comprising up to 70% of the total costs of treating patients with schizophrenia in the community [28,29]. This growth in the utilisation of atypical antipsychotic drugs appears to be driven by publications suggesting greater efficacy and functional recovery as well as lower side-effects compared with typical antipsychotics and other drugs [30-34]. These clinical improvements have resulted in improved compliance and persistence, although this has been challenged [35-37]. As a result in June 2002, the National Institute for Health and Clinical Excellence (NICE) in the UK recommended the prescribing of atypical (newer) antipsychotic drugs in people with newly diagnosed schizophrenia and those having side effect problems with typical (older) antipsychotic drugs [38]. NICE recently updated its guidance for patients with newly diagnosed schizophrenia stating that professionals should discuss the benefits and side-effect profile of each appropriate drug before a final choice is made [39]. There was no additional guidance encouraging the prescribing of any one particular antipsychotic drug over another apart from clozapine for refractory patients [39]. Similar advice was also given by the Medical Directors’ Council of the National Association of State Mental Health Programme Directors in the US [40].

There has also been growing use of atypical antipsychotic drugs in wider populations including patients with bipolar disorders [34,41-44].

However, there have been concerns about the quality of the clinical trial evidence with atypical antipsychotic drugs and the extent of any differences in daily practice between typical and atypical antipsychotic drugs [38]. There has also been criticism about the use of higher doses of haloperidol (typical antipsychotic) as a comparator in the studies with second generation (atypical antipsychotics) thereby biasing the results [45]. In addition, only a limited number of initial studies used medium-potency first generation (typical) antipsychotic drugs as the comparator [45,46]. There can also be a greater incidence of weight gain, hyperlipidaemia and Type 2 diabetes with atypical antipsychotic drugs versus typical (older) antipsychotic drugs [25,26,39,46-48]. 

The risk of QT prolongation and subsequent arrhythmia-related events, i.e. Torsade de Pointes (TdP) and Sudden Cardiac Death, is increasingly seen as important when physicians are prescribing atypical antipsychotic drugs [49,50]. In the past, these drugs have been perceived as generally having a favourable cardiac safety profile compared with typical antipsychotic drugs. However, this is changing with a recent study suggesting increased risk of sudden cardiac deaths among current users of atypical antipsychotic drugs [51]. The findings have been further corroborated by different pharmacovigilance analyses showing similar reporting ratios between typical and atypical antipsychotic medicines in clinical practice [52-54]. As a result, raising additional issues regarding the prescribing of these drugs that was previously unknown for this risk, e.g. olanzapine. Recent studies have also shown the highest risk of mortality among patients with schizophrenia was with quetiapine, and the lowest with clozapine [55]. However, there have been concerns regarding patient selection in this cohort study. Haloperidol and risperidone had slightly lower adjusted hazard ratios than quetiapine [55].

These debates about the clinical benefits of typical versus atypical antipsychotic drugs have continued with findings from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. The findings showed limited differences in effectiveness between the various antipsychotic drugs, although this study is not without criticism [25,56-58].  However, the study did show that the variation in the effectiveness of the different antipsychotic medicines between individual patients can be substantial [57]. In addition, the number of side-effects seen can also differ substantially between patients [57]. Consequently, the authors recommend treatment of patients with schizophrenia should be individualized [57]. These findings are endorsed by Cochrane Collaboration reviews and other studies suggesting tentatively that olanzapine may be more efficacious than some other second generation antipsychotic drugs [59-61]. However, caution is needed with interpreting the findings in view of the high drop-out rates in the reviewed studies. There have also been mixed findings with risperidone [62]. These findings suggest that atypical antipsychotic drugs should not be considered as a homogeneous drug class unlike the PPIs, statins, ACEIs or ARBs [1,3-6,10,14-16,23,63]. This is further endorsed by the heterogeneity of pharmacological activity among the different atypical antipsychotic drugs [31,32,39,45,47].

Other authors though believe the modest health gains reported for the atypical antipsychotic drugs do not adequately reflect the improvements in quality of life perceived by patients, clinicians or carers [64], leading to their increasing use. In view of this, it is likely the prescribing of atypical antipsychotic drugs will continue growing [25,30,65-68]. 

Consequently, the availability of generic atypical antipsychotic drugs should be welcomed in Sweden. This is because generics can be priced as low as 4 to 13% of their pre-patent loss prices following compulsory generic substitution [2], which will also apply to risperidone. Prices of generics are falling further with the recent instigation of monthly auctions among generic manufacturers to secure 70% to 80% of the prescribed volume for a particular molecule in the month following wining the auction [14,18]. Clozapine was the first atypical antipsychotic drug to lose its patent. Published studies have shown no difference in outcomes between the originator and generics once the problem with the first formulation in the US had been resolved [69-73]. More recently, generic olanzapine and generic risperidone became available with again no apparent patient issues in practice [25,73-76], although some authors are more cautious [75,77]. However, it is recognised that schizophrenia and bipolar disorders are complex diseases to treat. Alongside this as mentioned, atypical antipsychotic drugs should not be considered as a single class. As a consequence, it is recognised there is a need to tailor treatment approaches to optimise outcomes [39,40, 48,51-55,57]. In addition, switching patients between different anti-psychotic drugs should never be considered if their condition is stable [C. Barbui – personal communication].

In view of this, the principal objective of this paper is to assess the changes in the utilisation pattern of risperidone in Sweden before and after oral generic risperidone was reimbursed alongside any specific demand-side measures. As a result, compare and contrast the findings with those previously seen for the PPIs, statins and renin-angiotensin inhibitor drugs. In addition (a) assess the impact of the various measures on the price reduction for oral generic risperidone over time as well as overall expenditure on atypical antipsychotic drugs, and again compare the results with the findings from other generics; (b) suggest additional measures that could potentially be introduced to further enhance the prescribing of generic atypical antipsychotic drugs first line where appropriate; and (c) provide guidance to the counties (regions) in Sweden as well as other European countries on the implications of the findings. We do not expect that the utilisation of risperidone will decrease once generic formulations become available because compulsory generic substitution has been well accepted by both patients and physicians in Sweden [1,2,11,14,78,79].

Methods

We principally used an interrupted time series design to analyse the changes in monthly reimbursed prescriptions of all patients in Sweden contained in the national Swedish Pharmacy Register dispensed at least one atypical antipsychotic (N05AH03 to 06, N05AL05, N05AX08,11 to 13) [80] between January 2007, i.e. two years before generic risperidone became available in January 2009 to August 2011, 31 months after generic risperidone. Clozapine was not included in the analysis as it is reserved for patients not responding to other atypical antipsychotic drugs given its side-effect profile [25,32,69,71,81-83]. Ziprasidone (N05AE04) was also not included. This was in view of its classification and limited utilisation in practice in Sweden. 

An additional analysis was undertaken in Stockholm County Council, which is the largest region in Sweden at approximately 2 million people [2], using the Swedish Pharmacy Register to assess the impact on expenditure once olanzapine (October 2011) and immediate release quetiapine (April 2012) became available as generics, i.e. after the main study had finished. The objective being to ascertain whether any further demand-side measures were needed to help conserve resources as more generic atypical antipsychotic drugs were becoming available.

The utilisation of atypical antipsychotic drugs was assessed using defined daily doses (DDDs), with DDDs defined as ‘the average maintenance dose of a drug when used in its major indication in adults’, as this measure is recognised as the international standard to assess utilisation patterns within and between countries [80,84]. 2011 DDDs were used in line with international guidance [84-86]. DDDs were not converted into DDDs/ 1000 inhabitants/ year as total utilisation data was needed for the statistical analysis.

Any specific demand-side measures will be collated under the 4Es; namely Education, Engineering, Economics and Enforcement [87]. These were based on feedback from the various authorities and consolidated by two of the co-authors (MP and BW) into a narrative review. Their definitions and examples include [2,4-6,8-14,87,88]:
	Education, i.e. programmes that influence prescribing such as the distribution of printed guidelines and guidance including the ‘Wise List’ in Stockholm; academic detailing and the monitoring of prescribing against agreed guidance
	Engineering, i.e. organizational or managerial interventions. This includes physician prescribing and quality targets
	Economics, i.e. financial incentives such as financial incentives for physicians for achieving agreed prescribing targets 
	Enforcement, i.e. regulations including those enforced by law such as compulsory generic substitution in pharmacies. In addition, prescribing restrictions for patented statins, angiotensin receptor blockers (ARBs) and duloxetine in depression

Serial autocorrelations of risperidone DDDs were assessed in the interrupted time series design using an ARIMA model and a Box-Jenkins-Tiao strategy [89]. DDDs were plotted over time in months. The graphs were visually inspected to assess the trends or the nonstationarity of the data.  Alongside this, a segmented regression analysis of the interrupted time series was used to assess the effect of the reimbursement of generic risperidone and any demand-side measures instigated in January 2009 onwards. Common segmented regression models were used to fit a least-squares regression line to each segment of the independent variable (time t), assuming a linear relationship between time and the outcome within each segment. The effect of the intervention (generic risperidone and any demand-side measures) was assessed with using the model: Yt = β0 + β1 (timet = 0, 1, 2, …, 56) + β2 (intervention 1t) + β3 (time after intervention 1 t) + et, where Yt was risperidone DDDs per month t, time is a continuous variable indicating time (in months) at time t from the start until the end of the observation period, intervention is an indicator variable for time t occurring before (t = 0 month) or after (t = 1 month) the reimbursement of generic risperidone in January 2009, and et is the error term at time t [90]. The Durbin-Watson statistic was calculated to test for a serial autocorrelation of the error terms in the regression models [91]. The statistical package IBM SPSS Statistics version 19.0 was used for all analyses. A P value of <0.05 was considered significant [92].

We are confident we can undertake this type of analysis as any specific demand-side measures introduced in Sweden were instigated in direct response to the availability of oral generic risperidone.

Total expenditure was calculated for risperidone over time as well as for originator and generic oral risperidone after generic oral risperidone became available. This included long acting risperidone injections (LARI) as this commands a premium price compared with oral therapies. Expenditure/ DDD was also calculated for the atypical antipsychotic drugs combined before and after oral generic risperidone, as well as for the various risperidone preparations, to assess price reductions over time. These were expressed in Swedish Kroner (SEK). We chose to measure total expenditure rather than reimbursed expenditure as we wanted to assess the extent to which the manufacturer of originator risperidone would drop its price to compete. This is because we believed the vast majority of patients would not pay the price difference between the current lowest priced generic and a higher priced originator [2,3, 78], in line with previous research findings [2,25].  Consequently, the only way the originator company could preserve some market share would be to minimise any price differential between itself and the lowest price generics. We also chose SEK rather than Euros as we wanted to ascertain price level reductions without the influence of any currency fluctuation rates, especially given the current financial situation with the Euro in recent years in Europe. There has been no allowance for inflation as we wanted to compute the actual influence of the various policies in Sweden on prices/ DDD over time. In addition, the tendency among health authorities across Europe is to cut prices for both patented drugs and generics when pharmaceutical expenditure is rising more rapidly than agreed budgets [3-6,11,16,93-95]. Alongside this, a number of European countries establish their initial prices for generics based on originator pre-patent loss prices [3-6,16,63]. Consequently no allowance for inflation is in line with previous publications [3-6,11,16-18,76,94,95].

Total expenditure on atypical antipsychotic drugs was also calculated to assess the influence of both supply-side and demand-side measures on overall expenditure after the availability of generic oral risperidone.

Results

 There were no specific activities among the counties to encourage the prescribing of oral risperidone first line where appropriate once generic formulations became available. Risperidone was already recommended in county (regional) formularies and guidelines for schizophrenia based on the CATIE and other studies. This reflects the need to individualise treatment for both schizophrenia and bipolar disorders, with for instance quetiapine recommended alongside lithium for the management of bipolar disorders in Stockholm County Council’s Wise List [12].

Overall, the utilisation of the selected atypical antipsychotic drugs grew by 30% during the course of the study (Table 1), 20% after the availability of generic oral risperidone. The growth was driven by increased use of all other atypical antipsychotic drugs apart from risperidone. The utilisation of risperidone decreased both in actual terms (DDDs – Table 1, Figures 1 and 2) as well as percentage terms over time versus the combined utilisation of the selected atypical antipsychotic drugs.



Table 1 – Utilisation of all risperidone formulations and other atypical antipsychotic drugs (accumulated 6 monthly basis DDD(million) before and after the availability of oral generic risperidone from January 2007 to August 2011 (AAPs = Selected atypical antipsychotic drugs)


NB. DDD = defined daily dose

Figure 1 – Monthly utilisation of different atypical antipsychotic drugs in Sweden January 2007 to August 2011 (DDDs million)


NB Generic risperidone became available in January 2009. DDD = defined daily dose

The utilisation of risperidone decreased from 25% of total atypical antipsychotic drugs mentioned in the methodology section (DDD basis) in January 2009 to 20% by August 2011 (Figure 2).



Figure 2 – Monthly utilisation of risperidone and other atypical antipsychotic drugs (DDD 000s) before and after the availability of generic oral risperidone (Month 0)


NB DDD= defined daily dose

The utilisation of risperidone appeared though to stabilise post generic availability (Figures 1 and 3), although this did not reach significance (Table 2, Figure 3).

Table 2 - Parameter estimates, standard errors and P-values from the segmented regression model predicting the extent of risperidone DDDs before and after oral generic risperidone reimbursed (Coefficient variable is risperidone items dispensed)

Model	Unstandardised Coefficients	Standardised coefficients	T	Significance	95% Confidence interval for B
	B	Std. Error	Beta			Lower Bound	Upper Bound
Time (Reimbursement)	-4101.5	8559.7	-0.097	-0.479	0.634	-21277.9	13074.8
Reimbursement	-1115.1	566.8	0.392	1.968	0.054	-22.13	2252.4
NB: Dependent variable: Risperidone DDDs. DDDs = defined daily doses. Significance (Sig.) at p<0.05



Figure 3 – Change in utilisation patterns for risperidone (items dispensed in DDDs) before and after generic oral risperidone was reimbursed in January 2009 (DDDs) – statistical analysis



NB. DDDs = defined daily dose. Visual inspection of the datasets between January 2006 and January 2011

Oral risperidone was 96% generic risperidone by volume (DDDs) by August 2011. 

Long-acting risperidone injections (LARI) constituted 20% of the total DDDs for risperidone in August 2011, similar to 19% just before generic oral risperidone became available.

Total expenditure on atypical antipsychotic drugs also increased during the course of the study. This increased by 13% (accumulated 6 monthly basis) 30 months after the availability of generic oral risperidone versus accumulated 6 monthly expenditure just before oral generic risperidone was available and reimbursed (Table 3). 



Table 3 – Accumulated 6 monthly expenditure on selected atypical antipsychotic drugs in Sweden (AAPs) before and after the availability of generic oral risperidone (SEKmillion)



The lower increase in total expenditure of atypical antipsychotic drugs compared with their utilisation after the availability of oral generic risperidone (Tables 1 and 3) was helped by decreasing total expenditure/ DDD for risperidone (Figure 4). This included both oral and LARI risperidone.

Figure 4 – Expenditure/ DDD (SEK) of risperidone and all other selected atypical antipsychotic drugs (AAPs) before and after the availability of oral generic risperidone



Total expenditure/ DDD for oral generic risperidone was SEK7.64/ DDD in August 2011. This was 80% below the pre-patent loss originator price. The price of the originator also fell, but only by 38% to SEK23.19/ DDD in August 2011. Prices for oral generic risperidone are likely to fall further with the recent instigation of monthly auctions among generic manufacturers in Sweden. Total expenditure/ DDD for LARI in August 2011 was SEK119.43, 15.6 times higher than expenditure/ DDD for generic oral risperidone. 

There was an immediate reduction in expenditure on olanzapine in Stockholm County Council once generic olanzapine become available in October 2011 (Figure 5). Similarly for quetiapine, there was an appreciable reduction in expenditure for the immediate (IR) release formulation following the availability of generics in April 2012. There was though continued growth in expenditure on patented extended release (ER) quetiapine (Figure 5).

Figure 5 – Influence of the availability of generic olanzapine (October 2011) and generic quetiapine (immediate release – IR = April 2012) in Stockholm County Council on their expenditure (SEK)


NB Quetiapine ER tablets = extended release tablets. AUP = total expenditure in Swedish Krona (SEK)

Discussion

Multiple supply- and demand-side measures in Sweden appreciably enhanced prescribing efficiency for the PPIs, statins and renin-angiotensin inhibitor drugs. This was demonstrated by utilisation growing appreciably faster than expenditure in these three classes and groups where the products are seen as essentially similar in all or nearly all patients [2-7,9,10-16,22,63]. In addition for both the PPIs and statins, expenditure actually fell despite appreciably increased utilisation.

However, there was no appreciable change in the utilisation of risperidone following the availability of oral generic risperidone (Figures 1,2,3, Table 2). The fall in the utilisation of risperidone prior to the availability of generics may have been facilitated by the marketing activities of the companies [96-99]. However, it is difficult to substantiate this without further research. Having said this, the utilisation of risperidone did appear to stabilise following the availability of oral generic risperidone (Figures 1 and 3). No appreciable change in the utilisation of risperidone following generic availability in Sweden mirrors the situation seen in Austria, Belgium, Scotland, Spain and Ireland [76,96, 100]. This may reflect the advice from organisations such as NICE in the UK, the Medical Directors Council of the National Association of State Mental Health Programme Directors in the US, the conclusions from the various Cochrane reviews and the CATIE studies, that treatment with atypical antipsychotic drugs should be tailored to the individual patient [38,39,40, 44,56,61,62], which is seen in practice [48]. This may also reflect the fact that no specific demand-side measures were instigated nationally or regionally in Sweden to encourage the prescribing of oral generic risperidone first line where appropriate. Consequently, there appears to be no spill over with the influence of initiatives encouraging the prescribing of multiple sourced drugs first line from other disease areas to schizophrenia or bipolar disorders in Sweden. We believe this is an important finding given the extensive demand-side measures and initiatives ongoing in Sweden to encourage the prescribing of low costs generics first line where appropriate [3-6,11]. This though may be exacerbated on this occasion by the complexity of treating schizophrenia and bipolar disorders compared to treating acid-related stomach disorders, hypertension or hypercholesterolaemia, as well as no desire among physicians to switch patients between different atypical antipsychotic drugs when they are stable on a particular one. This is in view of the considerable inter-patient variability in both the effectiveness and side-effects of the different atypical antipsychotic drugs [39,40, 49, 57].

As a result, specific measures will be needed to encourage the prescribing of generic atypical antipsychotic drugs first line where multiple prescribing choices are available and appropriate. The objective of such measures will be to slow down or even reverse the growing utilisation of patented atypical antipsychotic drugs (Figures 1 and 2). Specific measures could include new guidance and guidelines advocating the prescribing of generic atypical antipsychotic drugs where there are no major patient issues. Other measures could include the introduction of prescribing restrictions limiting the prescribing of patented atypical antipsychotic drugs to second line where appropriate. This is similar to the recent restrictions limiting the prescribing of duloxetine in Sweden to third line in the management of depression [88]. However, care is needed as there have been adverse effects of policy changes introducing reimbursement restrictions on atypical antipsychotic drugs on patient care and expenditure in the US [101,102]; although this is not universal [103]. Accumulating data suggesting that deoxyribonucleic acid (DNA) information may be an important predictor of treatment response to atypical antipsychotic drugs in schizophrenia may also help in the future with the implementation of any prescribing guidance or restrictions [104]. Having said this, the influence of any demand-side measures on subsequent utilisation patterns is likely to be limited by the need to tailor treatments. This is unlike the prescribing of PPIs for acid-related stomach disorders or statins for hypercholesterolemia [4,5]. This is due to greater complexity in treating patients with schizophrenia or bipolar disorders. In addition, no possibility to switch patients between treatments if they are responding to a particular atypical antipsychotic drug unlike the situation seen with the statins or renin-angiotensin inhibitor drugs [10,14,16,17,23,24].

However, we believe that no specific measures are currently being planned nationally or regionally in Sweden with olanzapine losing its patent in October 2011 and quetiapine immediate (IR) release in April 2012. This is because these events resulted in a rapid fall in their expenditure as seen in Stockholm County Council (Figure 5). This may change with increasing recognition that there can be limited clinical benefit of atypical antipsychotic drugs in some patients, alongside potentially life-threatening events [49,50]. In addition following the launch of new premium priced atypical antipsychotic drugs including iloperidone from Novartis and zicronapine from Lundbeck. 

In the meantime, there could be a re-evaluation of the role and value of long-acting risperidone injections (LARI) in Sweden given their appreciable utilisation, 20% of total utilisation or risperidone on a DDD basis, coupled with their considerably higher acquisition cost than oral generic risperidone (15.6 times higher on a DDD basis in August 2011). Alongside this, patent protection until 2014 and ongoing concerns regarding the increased efficiency of LARI in practice versus oral risperidone [105]. This is because most of published studies with LARIs are open label and subject to sponsor bias and a number of independent randomised and observational studies have shown no clinical benefit versus oral treatments [105-114]. However, other studies have shown the opposite with reduced re-hospitalisation with LARI versus oral risperidone [115,116]. There could also be a re-evaluation of extended release quetiapine (once a day) versus the immediate release formulation (twice a day). This is because expenditure/ DDD for the ER formulation was 48.3SEK in August 2011 versus only 15.2 for the IR formulation and falling. Alongside this, no generic ER quetiapine will be available until 2016.

The high utilisation of generic risperidone suggests no problems in practice despite patients potentially getting different named generics on each occasion with the reforms to lower generic prices in Sweden [1-3,5,14,18]. This mirrors the findings in other European countries [25,72,89,90]. We believe this is particularly important given the appreciable reduction in expenditure/ DDD for oral generic risperidone versus pre-patent loss prices, which mirrors the price reductions of 87% to 96% seen for other generics in Sweden [2-7,10]. Similarly there also appears to be no effectiveness or safety problems to date with either generic olanzapine or IR quetiapine. However more research is needed before any definitive statements can be made.

We accept there are limitations with the study. These include the fact that we have only evaluated aggregated utilisation data without access to patient specific data to fully assess any changes in the prescribing patterns for oral generic risperidone before and after its availability. We also accept that we have not assessed patient outcomes following the availability of generic oral risperidone, and that we have only analysed recent expenditure on olanzapine and quetiapine in Stockholm County Council following the availability of their generics. We also acknowledge that we did not have a control group. However, this would have been difficult in the circumstances with substitution polices applying nationally. Finally, we acknowledge we have not looked specifically at issues of compliance with multiple sourced risperidone although feedback suggests no additional specific problems with the various generic formulations versus the originator. Never-the-less, we believe our findings are valid and provide guidance to others in the future.

Conclusion

Schizophrenia and bipolar disorders are complex diseases to treat which necessitate tailoring of treatments to individual patients. In addition, physicians have no desire to switch patients between treatments once they are stable on a particular medication. As a result, specific measures are needed to encourage the prescribing of generic atypical antipsychotic drugs when multiple choices are available and appropriate. There will be no change in utilisation patterns without these and authorities cannot rely on spill over effects between classes to effect changes in physician prescribing habits. This is similar to the situation with the prescribing of patented ARBs when losartan lost its patent. Again multiple measures were needed to enhance the utilisation of losartan versus other patented ARBs; otherwise limited change in its utilisation [14,63,117].

Specific measures to encourage the prescribing of generic atypical antipsychotic drugs first line could include guidelines or prescribing restrictions. However, their influence will be affected by the need to tailor treatment. In addition, care is needed with the implementation of any prescribing restrictions given the complexities of the disease areas. We believe though that no specific measures are currently planned nationally or regionally in Sweden in view of the complexities of the disease areas and more atypical antipsychotic drugs becoming available as generics. However, the situation may change with a re-evaluation of the place of LARI and quetiapine ER now that generic oral risperidone and IR quetiapine are available at considerably lower prices than these two patented formulations. This though remains to be seen. The situation may also change if new atypical antipsychotic drugs are launched at considerably higher prices than currently available generic atypical antipsychotic drugs.
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